Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metronidazole + miconazole is a fixed-dose combination of two small molecule drugs used primarily for the treatment of vaginal and skin infections caused by mixed bacterial and fungal pathogens. Metronidazole is an antibiotic that exerts its effect by damaging the DNA of bacteria and certain protozoa, leading to cell death. Miconazole is an antifungal agent that inhibits the synthesis of ergosterol, a key component in fungal cell membranes, thereby disrupting membrane integrity and inhibiting fungal growth. This combination provides broad-spectrum coverage against both anaerobic bacteria (via metronidazole) and fungi (via miconazole), making it effective for conditions such as bacterial vaginosis with concurrent candidiasis or other mixed infections[1][4][6]. The combination is available in various formulations including vaginal suppositories and creams.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metronidazole + miconazole.